Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Intelligent Bio Solutions's Revenue for the
three
months ended in Mar. 2026 was $1.06 Mil. Intelligent Bio Solutions's average Accounts Receivable for the
three
months ended in Mar. 2026 was $0.67 Mil.
Hence, Intelligent Bio Solutions's Receivables Turnover for the
three
months ended in Mar. 2026 was 1.59.
Intelligent Bio Solutions (NAS:INBS) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Intelligent Bio Solutions Receivables Turnover Related Terms
Intelligent Bio Solutions Receivables Turnover Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Intelligent Bio Solutions Receivables Turnover Chart
INBS vs ITOC, WOK, BMRA: Receivables Turnover Comparison
For the Medical Devices subindustry, Intelligent Bio Solutions's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Intelligent Bio Solutions Receivables Turnover vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Intelligent Bio Solutions's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Intelligent Bio Solutions's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Intelligent Bio Solutions (INBS) has a Receivables Turnover of 1.59 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Intelligent Bio Solutions and its competitors. According to the industry distribution chart, Intelligent Bio Solutions ranks #336 out of 812 companies in the Medical Devices & Instruments industry, placing it in the top 41.4%.
Is Intelligent Bio Solutions' Receivables Turnover too high?
Intelligent Bio Solutions' current Receivables Turnover is 1.59. The Medical Devices & Instruments industry median Receivables Turnover is 5.51. Intelligent Bio Solutions' value of 1.59 is 71.1% below this industry median. Based on the distribution chart, Intelligent Bio Solutions ranks #336 out of 812 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Intelligent Bio Solutions has a GF Score™ of 48/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Intelligent Bio Solutions' Receivables Turnover compare to ITOC and WOK?
According to the Medical Devices & Instruments industry distribution chart, Intelligent Bio Solutions ranks #336 out of 812 companies for Receivables Turnover. This puts Intelligent Bio Solutions in the upper half of its industry. The industry median Receivables Turnover is 5.51. Intelligent Bio Solutions' value of 1.59 is 71.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Medical Devices & Instruments company?
The median Receivables Turnover among Medical Devices & Instruments companies is 5.51, based on 812 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Intelligent Bio Solutions's current Receivables Turnover of 1.59 is 71.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Intelligent Bio Solutions and its competitors. For the Medical Devices & Instruments industry, the median Receivables Turnover is 5.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Intelligent Bio Solutions's current Receivables Turnover is 1.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Intelligent Bio Solutions stock overvalued right now?
Based on GuruFocus' analysis, Intelligent Bio Solutions (INBS) is currently considered Modestly Undervalued. The stock's GF Value™ is $2.62, compared to a current price of $2.11 — trading 19.5% below its estimated fair value. The current Receivables Turnover is 1.59 and 71.1% below the Medical Devices & Instruments industry median of 5.51. Intelligent Bio Solutions' overall GF Score™ is 48/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Intelligent Bio Solutions (INBS), the current Receivables Turnover is 1.59 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Intelligent Bio Solutions (INBS) Overvalued in 2026?
Based on GuruFocus' analysis, Intelligent Bio Solutions stock appears to be undervalued.
The current stock price of $2.11 is trading 19.5% below its estimated GF Value™ of $2.62.
GuruFocus considers Intelligent Bio Solutions to be Modestly Undervalued.
Key valuation signals for INBS:
Receivables Turnover: 1.59
GF Value™: $2.62 vs. price of $2.11 (19.5% below fair value)
Industry Position: 71.1% below the Medical Devices & Instruments median (#336 of 812)
No single metric tells the full story. See the INBS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Intelligent Bio Solutions Inc is a life sciences company developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. Its Biosensor Platform is developing and launching diagnostic tests urgently needed to help people living with chronic diseases. It also engages in the advancement of portable drug abuse testing through the analysis of fingerprint sweat. The test is non-invasive, hygienic, and fast, and screens for recent use of opioids, cocaine, methamphetamines, benzodiazepines, and marijuana. The company operates through new reportable segments: United Kingdom; Asia Pacific (APAC); Americas; and Rest of World, of which United Kingdom derives maximum revenue.
48GF Score
Get the complete analysis for INBS
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
INBS has been successfully added to your 
